Europe
HERA-GITRL Shows Strong Single-Agent Anti-Tumor Activity in Vitro and in Vivo and is Superior to Bivalent Clinical Benchmark Antibody
Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.
Sanofi will be responsible for leading the clinical program and funding all studies needed to support the over-the-counter switch in the United States and will also be responsible for the regulatory submissions.
At 96 weeks, 60% of the heavily pretreated HIV patients dosed with ViiV’s experimental treatment achieved virologic suppression.
Today, Civica Rx announced a five-year deal with London, UK-based Hikma Pharmaceuticals to manufacture and supply Civica’s members with 14 sterile injectable drugs as a private label distributor.
In the pharmaceutical industry, continuous and secure data acquisition and documentation is crucial for production and storage requirements, and also for research and development.
Online self-management helps; for some the online system plus nurse telecare helps more
Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM’s unique technology platform
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
Congenica, a digital health company enabling accelerated genomic data interpretation, today announced it has renamed its software platformCongenica® and expanded its capabilities to include CNV calling for exome and gene panel sequencing.
PRESS RELEASES